Advanced Prostate Cancer
42
15
18
11
Key Insights
Highlights
Success Rate
85% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
4.8%
2 terminated out of 42 trials
84.6%
-2.0% vs benchmark
14%
6 trials in Phase 3/4
45%
5 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 11 completed trials
Clinical Trials (42)
DEC003M in Prostate Cancer
Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer.
Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
Study of XNW5004 Tablets in Advanced Prostate Cancer
A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer
Lab Research Using Mini-tumors to Study Prostate Cancer Treatments
Engage Psychosocial Intervention for Cancer Symptoms
A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer
Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)
SRAM study_Postate Cancer
Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer
Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors